Cargando…

Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan

OBJECTIVE: To identify factors affecting adherence to medication, a subjective questionnaire survey was administered to schizophrenia patients regarding the prescribed antipsychotic formulations. METHODS: We evaluated the patients’ satisfaction and dissatisfaction with prescribed antipsychotic formu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatano, Masakazu, Takeuchi, Ippei, Yamashita, Kanade, Morita, Aoi, Tozawa, Kaori, Sakakibara, Takashi, Hajitsu, Genta, Hanya, Manako, Yamada, Shigeki, Iwata, Nakao, Kamei, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553540/
https://www.ncbi.nlm.nih.gov/pubmed/34690116
http://dx.doi.org/10.9758/cpn.2021.19.4.610
_version_ 1784591607163518976
author Hatano, Masakazu
Takeuchi, Ippei
Yamashita, Kanade
Morita, Aoi
Tozawa, Kaori
Sakakibara, Takashi
Hajitsu, Genta
Hanya, Manako
Yamada, Shigeki
Iwata, Nakao
Kamei, Hiroyuki
author_facet Hatano, Masakazu
Takeuchi, Ippei
Yamashita, Kanade
Morita, Aoi
Tozawa, Kaori
Sakakibara, Takashi
Hajitsu, Genta
Hanya, Manako
Yamada, Shigeki
Iwata, Nakao
Kamei, Hiroyuki
author_sort Hatano, Masakazu
collection PubMed
description OBJECTIVE: To identify factors affecting adherence to medication, a subjective questionnaire survey was administered to schizophrenia patients regarding the prescribed antipsychotic formulations. METHODS: We evaluated the patients’ satisfaction and dissatisfaction with prescribed antipsychotic formulations, and patients answered the Drug Attitude Inventory-10 Questionnaire (DAI-10). Inclusion criteria for patients are as follows age between 20 and 75 years and taking antipsychotic agents containing the same ingredients and formulations, for at least 1 month. RESULTS: In total, 301 patients answered the questionnaire survey. Tablets were found to be the most commonly used antipsychotic formulations among schizophrenia patients (n = 174, 57.8%), followed by long-acting injections (LAIs, n = 93, 30.9%). No significant differences in the formulation satisfaction level and DAI-10 scores were observed between all formulations. Formulations, except for LAI, were selected by physicians in more than half of the patients. Patients who answered “Decided by consultation with physicians” had significantly higher satisfaction levels and DAI-10 scores compared to those who answered “Decided by physicians” (4.11 ± 0.77 vs. 3.80 ± 1.00, p = 0.0073 and 6.20 ± 3.51 vs. 4.39 ± 4.56, p < 0.001, respectively). Satisfaction levels moderately correlated with DAI-10 scores (r = 0.48, p < 0.001). CONCLUSION: No formulation had a high satisfaction level in all patients, and it is important to be reflect the patients’ individual preferences in pharmacotherapy. Shared decision-making in the selection of the formulations is seen to be useful for improving medication adherence.
format Online
Article
Text
id pubmed-8553540
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Korean College of Neuropsychopharmacology
record_format MEDLINE/PubMed
spelling pubmed-85535402021-11-30 Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan Hatano, Masakazu Takeuchi, Ippei Yamashita, Kanade Morita, Aoi Tozawa, Kaori Sakakibara, Takashi Hajitsu, Genta Hanya, Manako Yamada, Shigeki Iwata, Nakao Kamei, Hiroyuki Clin Psychopharmacol Neurosci Original Article OBJECTIVE: To identify factors affecting adherence to medication, a subjective questionnaire survey was administered to schizophrenia patients regarding the prescribed antipsychotic formulations. METHODS: We evaluated the patients’ satisfaction and dissatisfaction with prescribed antipsychotic formulations, and patients answered the Drug Attitude Inventory-10 Questionnaire (DAI-10). Inclusion criteria for patients are as follows age between 20 and 75 years and taking antipsychotic agents containing the same ingredients and formulations, for at least 1 month. RESULTS: In total, 301 patients answered the questionnaire survey. Tablets were found to be the most commonly used antipsychotic formulations among schizophrenia patients (n = 174, 57.8%), followed by long-acting injections (LAIs, n = 93, 30.9%). No significant differences in the formulation satisfaction level and DAI-10 scores were observed between all formulations. Formulations, except for LAI, were selected by physicians in more than half of the patients. Patients who answered “Decided by consultation with physicians” had significantly higher satisfaction levels and DAI-10 scores compared to those who answered “Decided by physicians” (4.11 ± 0.77 vs. 3.80 ± 1.00, p = 0.0073 and 6.20 ± 3.51 vs. 4.39 ± 4.56, p < 0.001, respectively). Satisfaction levels moderately correlated with DAI-10 scores (r = 0.48, p < 0.001). CONCLUSION: No formulation had a high satisfaction level in all patients, and it is important to be reflect the patients’ individual preferences in pharmacotherapy. Shared decision-making in the selection of the formulations is seen to be useful for improving medication adherence. Korean College of Neuropsychopharmacology 2021-11-30 2021-11-30 /pmc/articles/PMC8553540/ /pubmed/34690116 http://dx.doi.org/10.9758/cpn.2021.19.4.610 Text en Copyright© 2021, Korean College of Neuropsychopharmacology https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Hatano, Masakazu
Takeuchi, Ippei
Yamashita, Kanade
Morita, Aoi
Tozawa, Kaori
Sakakibara, Takashi
Hajitsu, Genta
Hanya, Manako
Yamada, Shigeki
Iwata, Nakao
Kamei, Hiroyuki
Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan
title Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan
title_full Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan
title_fullStr Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan
title_full_unstemmed Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan
title_short Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan
title_sort satisfaction survey on antipsychotic formulations by schizophrenia patients in japan
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553540/
https://www.ncbi.nlm.nih.gov/pubmed/34690116
http://dx.doi.org/10.9758/cpn.2021.19.4.610
work_keys_str_mv AT hatanomasakazu satisfactionsurveyonantipsychoticformulationsbyschizophreniapatientsinjapan
AT takeuchiippei satisfactionsurveyonantipsychoticformulationsbyschizophreniapatientsinjapan
AT yamashitakanade satisfactionsurveyonantipsychoticformulationsbyschizophreniapatientsinjapan
AT moritaaoi satisfactionsurveyonantipsychoticformulationsbyschizophreniapatientsinjapan
AT tozawakaori satisfactionsurveyonantipsychoticformulationsbyschizophreniapatientsinjapan
AT sakakibaratakashi satisfactionsurveyonantipsychoticformulationsbyschizophreniapatientsinjapan
AT hajitsugenta satisfactionsurveyonantipsychoticformulationsbyschizophreniapatientsinjapan
AT hanyamanako satisfactionsurveyonantipsychoticformulationsbyschizophreniapatientsinjapan
AT yamadashigeki satisfactionsurveyonantipsychoticformulationsbyschizophreniapatientsinjapan
AT iwatanakao satisfactionsurveyonantipsychoticformulationsbyschizophreniapatientsinjapan
AT kameihiroyuki satisfactionsurveyonantipsychoticformulationsbyschizophreniapatientsinjapan